Story perspectives

Merck's Sac-TMT Beats Chemo, Extends Survival

5/19/2026

Summary

Merck Scores Survival

Merck reported its Phase 3 TroFuse-005 trial met survival and progression-free survival endpoints in advanced endometrial cancer.
The trial randomized 776 platinum- and anti-PD-1/L1-treated patients to sac-TMT or doxorubicin/paclitaxel, with interim data showing sac-TMT significantly improved survival and no new safety signals.
Merck secured sac-TMT via a $1.4 billion 2022 Kelun-Biotech deal and later pledged up to $9.3 billion for seven ADCs in the TroFuse program, now running multiple Phase 3 trials.

Summary

Merck Accelerates

The FDA placed sacituzumab tirumotecan in its National Priority Voucher program, shortening review to 1-2 months.
Merck plans to file a regulatory submission later in 2026 for a 2027 launch.
RBC Capital Markets projects $7.2 billion in sales by 2034.
The American Cancer Society expects 68,000 U.S. endometrial cancer cases and about 14,000 deaths in 2026.

1 of 2

Merck Scores Survival

Merck reported its Phase 3 TroFuse-005 trial met survival and progression-free survival endpoints in advanced endometrial cancer.
The trial randomized 776 platinum- and anti-PD-1/L1-treated patients to sac-TMT or doxorubicin/paclitaxel, with interim data showing sac-TMT significantly improved survival and no new safety signals.
Merck secured sac-TMT via a $1.4 billion 2022 Kelun-Biotech deal and later pledged up to $9.3 billion for seven ADCs in the TroFuse program, now running multiple Phase 3 trials.

1 / 2